Effect of atrial natriuretic peptide on dopa potentiation in mice.
The effect of rat atrial natriuretic peptide (ANP1-28) on the pargyline-DOPA potentiation test was studied following its administration into the lateral brain ventricle in mice. Thirty minutes after pargyline pretreatment, three doses of ANP (200, 500, or 1,000 ng/mouse) were administered simultaneously with DOPA and animals were then observed for 2 h. ANP in doses of 500 and 1,000 ng markedly enhanced the effect of DOPA. The maximum intensity of the effect was registered 30-45 min following administration of the peptide. The data suggest that ANP might be regarded as a dopaminergic-modulating agent in the CNS.
Bidzseranova
A
A
Institute of Pathophysiology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Gueron
J
J
Tóth
G
G
Penke
B
B
Telegdy
G
G
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004357:Drug Synergism; D051379:Mice; D008815:Mice, Inbred Strains; D010293:Pargyline / Q000494:pharmacology*; D013239:Stereotyped Behavior / Q000187:drug effects
D004295:Dihydroxyphenylalanine; D009320:Atrial Natriuretic Factor; D010293:Pargyline; D001058:Apomorphine